Seth Loring Harrison

Insider Reports History

Location
230 Park Avenue, Suite 2800, New York, NY
Signature
/s/ Jonathan Young, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Seth Loring Harrison:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Akero Therapeutics, Inc. Director Common Stock 148K $6.65M $44.92 Jun 3, 2025 Indirect
Akero Therapeutics, Inc. Director Common Stock 146K $6.54M $44.92 Jun 3, 2025 Direct
Stoke Therapeutics, Inc. Director Director Stock Option (Right to Buy) 29.7K Jun 3, 2025 Direct
Akero Therapeutics, Inc. Director Stock Option (Right to Buy) 26K Jun 8, 2024 Direct

Insider Reports Filed by Seth Loring Harrison

Symbol Company Period Transactions Value $ Form Type Date Filed Role
AKRO Akero Therapeutics, Inc. Jun 3, 2025 1 $0 4 Jun 5, 2025 Director
STOK Stoke Therapeutics, Inc. Jun 3, 2025 1 $0 4 Jun 4, 2025 Director
AKRO Akero Therapeutics, Inc. Jun 8, 2024 1 $0 4 Jun 11, 2024 Director
STOK Stoke Therapeutics, Inc. Jun 5, 2024 1 $0 4 Jun 7, 2024 Director
AKRO Akero Therapeutics, Inc. Jun 23, 2023 1 $0 4 Jun 27, 2023 Director
STOK Stoke Therapeutics, Inc. Jun 13, 2023 1 $0 4 Jun 15, 2023 Director
AKRO Akero Therapeutics, Inc. Nov 30, 2022 4 -$1.09M 4 Dec 2, 2022 Director
AKRO Akero Therapeutics, Inc. Oct 28, 2022 4 -$1.78M 4 Nov 1, 2022 Director
AKRO Akero Therapeutics, Inc. Oct 25, 2022 14 -$12.2M 4 Oct 27, 2022 Director
STOK Stoke Therapeutics, Inc. Jun 7, 2022 1 $0 4 Jun 8, 2022 Director
AKRO Akero Therapeutics, Inc. Jun 2, 2022 1 $0 4 Jun 3, 2022 Director
STOK Stoke Therapeutics, Inc. Jun 8, 2021 1 $0 4 Jun 25, 2021 Director, 10%+ Owner
AKRO Akero Therapeutics, Inc. Jun 1, 2021 1 $0 4 Jun 3, 2021 Director